<DOC>
	<DOCNO>NCT02585869</DOCNO>
	<brief_summary>The purpose study evaluate effect gemcabene HDL‐C , LDL‐C , TG , lipid level patient low HDL‐C</brief_summary>
	<brief_title>Efficacy Safety Gemcabene Patients With Low HDL‐C Either Normal Elevated Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Men naturally postmenopausal surgically menopausal woman 18 80 year age Baseline HDL‐C &lt; 35 mg/dL ( 0.9 mmol/L ) Creatine phosphokinase ( CPK ) &gt; 3 × upper limit normal ( ULN ) Body Mass Index ( BMI ) &gt; 35 kg/m2 Uncontrolled Hypertension &gt; 95 mm Hg Uncontrolled diabetes mellitus ( HbA1c &gt; 10 % ) Renal dysfunction ( blood urea nitrogen [ BUN ] creatinine &gt; 2 × ULN ) ; Hepatic dysfunction ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 2 × ULN ) Uncontrolled hypothyroidism ( TSH &gt; 1.5 × ULN ) Myocardial infarction , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , major cardiovascular event result hospitalization previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lipid Regulator</keyword>
	<keyword>TG</keyword>
</DOC>